【翰森制药授予Regeneron在研GLP-1/GIP双受体激动剂HS-20094海外独占许可】 翰森制药宣布与Regeneron Pharmaceuticals, Inc.订立许可协议*,授予Regeneron开发、生产及商业化HS-20094的全球独占许可。根据协议,翰森制药将获得8,000万美元首付款,并有资格根据该产品开发、注册审批和商业化进展收取最高19.3亿美元里程碑付款,以及未来潜在产品销售的双位数百分比特许权使用费。

金融界
Jun 02
翰森制药宣布与Regeneron Pharmaceuticals, Inc.订立许可协议*,授予Regeneron开发、生产及商业化HS-20094的全球独占许可。根据协议,翰森制药将获得8,000万美元首付款,并有资格根据该产品开发、注册审批和商业化进展收取最高19.3亿美元里程碑付款,以及未来潜在产品销售的双位数百分比特许权使用费。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10